Clinical trials: Advanced Digestive System Tumor
Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
This phase I pilot trial studies the side effects of cluster of differentiation 8 (CD8)+ T cells in treating patients with gastrointestinal tumors that have spread to other places in the body.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma
- Trial name
- NCT02757391
- Testing
- Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma, Hepatic Metastasis
Palliative Radiotherapy (RT) for Liver Metastases (Mets) and Hepatocellular Carcinoma (HCC)(COLD 4)
Palliative radiotherapy is radiation treatment given to help reduce pain or discomfort, or other symptoms related to cancer. This is used commonly for cancer that has spread to the bones and brain, and for many other primary…
- Trial name
- NCT00923897
- Testing
- Palliative RT
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Carcinoma, Hepatocellular
A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
Intravenous infusion of CART cells in the treatment of solid tumors may be not a suitable choice. Because by intravenous infusion, T cells first entered into the blood circulation, but the number of T cells accumulated at the…
- Trial name
- GPC3-CART (NCT02715362)
- Testing
- TAI-GPC3-CART cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai GeneChem Co., Ltd.
Carcinoma, Hepatocellular
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Mapatumumab is a fully human, agonist monoclonal antibody that activates the cell death pathway in tumor cells by specifically binding to TRAIL-R1 with high affinity.
- Trial name
- NCT01258608
- Testing
- Mapatumumab, Sorafenib
- Where
- 43 sites in United States, Germany and 5 more
- Volunteers
- 101 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Locally Advanced Pancreatic Cancer
Pancreatic Locally Advanced Irresectable Cancer Ablation
The aim of the PELICAN trial is to investigate the survival benefit of RFA plus standard palliative chemotherapy as compared to palliative chemotherapy alone in patients with LAPC after 2 months of induction chemotherapy.
- Trial name
- PELICAN (NCT03690323)
- Testing
- Radiofrequency ablation (RFA), FOLFIRINOX, Nab-paclitaxel plus Gemcitabine
- Where
- 2 sites in Netherlands
- Volunteers
- 228 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Esophageal Cancer
Study of TNFerade™ Gene Therapy, Radiation, 5-FU and Cisplatin in Esophageal Cancer
The primary purpose of this study is to assess the safety and feasibility of giving TNFerade™ with 5-FU, Cisplatin and radiation therapy to patients with locally advanced, esophageal cancer prior to surgical resection.
- Trial name
- NCT00051480
- Testing
- TNFerade
- Where
- 12 sites in United States
- Sponsor
- GenVec
Esophageal Cancer, Advanced Solid Tumor
Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function
To evaluate the pharmacokinetics and safety of Larotinib in subjects with mild and moderate hepatic function impairment and healthy subjects in a single-center, non-randomized, open, single-dose administration
- Trial name
- NCT05048368
- Testing
- Larotinib
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Biliary Tract Cancer
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
To evaluate the efficacy and safety TQB2102 for injection in the treatment of patients with Her2-positive biliary tract cancer.
- Trial name
- NCT06431490
- Testing
- TQB2102 for injection
- Where
- 43 sites in China
- Volunteers
- 102 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Malignant Solid Tumour, Liver Metastases
A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
A pharmacodynamic study to evaluate the effect of AV-299 on exploratory pharmacodynamic markers in subjects with advanced solid tumors who have liver metastases.
- Trial name
- NCT00969410
- Testing
- AV-299
- Where
- Spain
- Volunteers
- 19 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Ovarian Cancer, Fallopian Tube Neoplasms
Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")
Participants with ovarian cancer usually get the drugs carboplatin and paclitaxel as initial treatment. In many participants the tumor will shrink, or even disappear, after treatment with these drugs.
- Conditions
- Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasm
- Trial name
- NCT00391118
- Testing
- enzastaurin, carboplatin, paclitaxel
- Where
- 15 sites in Belgium, Germany and 3 more
- Volunteers
- 153 people
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer
Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if gemcitabine is more effective with or without capecitabine in treating pancreatic…
- Trial name
- NCT00032175
- Testing
- capecitabine, gemcitabine hydrochloride
- Where
- 30 sites in United Kingdom
- Volunteers
- 508 people
- Sponsor
- Cancer Research UK
Pancreatic Cancer, Colorectal Cancer
IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations
This is a single-arm, single-center, open-label clinical study aimed at evaluating the safety and efficacy of IX001 TCR-T (T cell receptor-engineered T-Cell) injection in patients with advanced pancreatic cancer and colorectal…
- Trial name
- NCT06487377
- Testing
- IX001 TCR-T cells
- Where
- China
- Sponsor
- Shanghai Pudong Hospital
Colorectal Cancer, Cholangiocarcinoma
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
- Conditions
- Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT06399757
- Testing
- APL-5125
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Apollo Therapeutics Ltd
Stage IIB Esophageal Cancer AJCC v7, Stage III Esophageal Cancer AJCC v7
Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer
This pilot clinical trial studies how well ferumoxytol-enhanced magnetic resonance imaging (MRI) works in imaging lymph nodes in patients with stage IIB-IIIC esophageal cancer.
- Conditions
- Stage IIB Esophageal Cancer AJCC v7, Stage III Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7
- Trial name
- NCT02857218
- Testing
- Ferumoxytol, Magnetic Resonance Imaging
- Sponsor
- OHSU Knight Cancer Institute
Colorectal Cancer, Liver Metastases
Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer
Research has found that patients with microsatellite instability (dMMR/MSI-H) type colorectal cancer can achieve long-term survival through immune checkpoint inhibitors (ICIs) treatment, but currently accounting for about 95% of…
- Conditions
- Colorectal Cancer, Liver Metastases, MSS
- Trial name
- REGOTORICOX (NCT05933980)
- Testing
- Rego+Tori+Cele
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Sun Yat-sen University
Colorectal Adenoma
the Serum Metabolite Based PrecogColo Dx Test for Advanced Colorectal Neoplasia Screening
This study is to Evaluate the diagnostic sensitivity of the serum metabolite based PrecogColo Dx test for advanced colorectal neoplasia Screening, including advanced adenoma and colorectal cancer.
- Trial name
- NCT05870696
- Testing
- PrecogColo Dx test
- Where
- 6 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Peking University Third Hospital
Colorectal Cancer, Advanced Solid Tumors
MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)
Study with an investigational drug in patients with recurrent or non-responsive colorectal cancer or other advanced solid tumors.
- Trial name
- NCT00099346
- Testing
- MK0457, VX-680 (Aurora Kinase Inhibitor)
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms, Non-small-cell Lung Cancer
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
This study aims to evaluate the safety, and early signals of anti-tumor activity of PF-07820435 when administered alone (Part 1A) or in combination with sasanlimab (Part 1B; Part 2) in patients with selected advanced or…
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT06285097
- Testing
- PF-07820435, Sasanlimab
- Where
- 10 sites in United States, Japan and 1 more
- Volunteers
- 9 people
- Sponsor
- Pfizer
Biliary Tract Neoplasms Immunotherapy
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer
This phase II study evaluates the efficacy and safety of Trastuzumab Rezetecan in combination with Adebrelimab and Lenvatinib as first-line therapy for patients with locally advanced or metastatic HER2-positive or HER2-low…
- Trial name
- NCT07670273
- Testing
- Trastuzumab Rezetecan, Adebrelimab, Lenvatinib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking Union Medical College Hospital
Gastric Carcinoma
A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Tislelizumab and CAPOX versus Tislelizumab combined with CAPOX as first-line treatment for patients with HER2-low advanced…
- Trial name
- NCT06944496
- Testing
- Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine, Tislelizumab+Oxaliplatin+Capecitabine
- Where
- China
- Volunteers
- 616 people
- Sponsor
- RemeGen Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.